Tito R. Mendoza

Tito R. Mendoza

Auto-generated profile, based on publicly available information

Tito R. Mendoza

Center for Cancer Research, National Cancer Institute, Rockville, MD 20850, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ADAmylou C. Dueck
Amylou C. Dueck
TMTito R. Mendoza
Tito R. Mendoza
SMSandra A Mitchell
Sandra A Mitchell
BRBryce B Reeve
Bryce B Reeve
KCKathleen M. Castro
Kathleen M. Castro
FGfor the National Cancer Institute PRO-CTCAE Study Group
for the National Cancer Institute PRO-CTCAE Study Group
In cancer clinical trials, adverse events (AEs) are collected and reported using the US National Cancer Institute’s (NCI’s) Common Terminology Criteria for Adverse Events (CTCAE).1 The CTCAE is a library of items representing 790 discrete AEs, each graded using an ordinal severity scale.2 Approximately 10% of AEs in the CTCAE are symptoms (eg, nausea, sensory neuropathy), which in trials have historically been reported by clinical investigators.3 However, there is empirical evidence that collection of this information directly from patients improves the precision and reliability of symptomatic AE detection in trials4-9and is feasible.10,11 Moreover, there is substantial evidence that clinical investigators may miss up to half of patients’ symptomatic AEs.5,6,12,13

1 May 2006 in European journal of pain
Verified
Journal Article
Closed access
TMTito Mendoza
Tito Mendoza
TMTracy Mayne
Tracy Mayne
DRDale Rublee
Dale Rublee
CCCharles Cleeland
Charles Cleeland

1 January 2004 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
TMTito R. Mendoza
Tito R. Mendoza
CCConnie Chen
Connie Chen
ABAndrew Brugger
Andrew Brugger
RHRichard Hubbard
Richard Hubbard
MSMichael Snabes
Michael Snabes
CCCharles S. Cleeland
Charles S. Cleeland
Patients undergoing major surgery often require several days of postoperative analgesia. However, few data exist on the longitudinal course of postoperative pain and the psychometric properties of pain assessment tools used in this setting. Our objective was to validate use of the modified Brief Pain Inventory through reanalysis of pain data from a multiple-dose, placebo-controlled, randomized trial of analgesia after coronary artery bypass graft surgery. Four hundred sixty-two patients who underwent coronary artery bypass graft surgery via median sternotomy were administered a shortened form of the original Brief Pain Inventory that contained 3 severity and 5 interference items. Additionally, patients were presented with a single-item measure of procedure-specific pain. Daily pain and interference ratings were available from days 4 to 14 postoperatively. We performed factor analysis to evaluate the consistency with which the modified Brief Pain Inventory items loaded on 2 separate factors corresponding to the original Brief Pain Inventory’s pain severity and pain interference subscales. We calculated 2 reliability measures, internal consistency and test–retest reliability, for each subscale. The modified Brief Pain Inventory consistently measured 2 underlying constructs, severity and interference, with Cronbach alphas of 0.85 or greater for the 2 Brief Pain Inventory scales, and test–retest stability coefficients ranging from 0.58 to 0.95 for each pair of consecutive assessment periods. The procedure-specific pain question showed substantial overlap with a general measure of pain severity, suggesting concurrent validity. The modified Brief Pain Inventory was stable and valid over the assessment period, suggesting that it can be used during the subacute postoperative period to assess postoperative pain among patients with coronary artery bypass graft surgery.

1 February 2011 in The Oncologist
Verified
Journal Article
Open access
PDF file
TMTito R. Mendoza
Tito R. Mendoza
XWXin Shelley Wang
Xin Shelley Wang
CLCharles Lu
Charles Lu
GPGuadalupe R. Palos
Guadalupe R. Palos
ZLZhongxing Liao
Zhongxing Liao
CCCharles S. Cleeland
Charles S. Cleeland
We conducted a study to establish the psychometric properties of a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with lung cancer (MDASI-LC). The MDASI measures 13 common “core” symptoms of cancer and its treatment. The MDASI-LC includes the 13 core MDASI symptom items and three lung cancer–specific items: coughing, constipation, and sore throat. MDASI-LC items were administered to three cohorts of patients with lung cancer undergoing either chemotherapy or chemoradiotherapy. Known-group validity and criterion (concurrent) validity of the MDASI-LC were evaluated using the Eastern Cooperative Oncology Group performance status and the 12-item Short-Form Health Survey. The internal consistency and test-retest reliability of the module were adequate, with Cronbach coefficient α-values of 0.83 or higher for all module items and subscales. The sensitivity of the MDASI-LC to changes in patient performance status (disease progression) and to continuing cancer treatment (effects of treatment) was established. Cognitive debriefing of a subset of participants provided evidence for content validity and indicated that the MDASI core items and three additional lung cancer–specific items were clear, relevant to patients, and easy to understand; only two patients suggested additional symptom items. As expected, the item “sore throat” was sensitive only for patients receiving chemoradiotherapy. The MDASI-LC is a valid, reliable, and sensitive symptom-assessment instrument whose use can enhance clinical studies of symptom status in patients with lung cancer and epidemiological and prevalence studies of symptom severity across various cancer types.

19 February 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
OGon behalf of the National Cancer Institute PRO-CTCAE Study Group
on behalf of the National Cancer Institute PRO-CTCAE Study Group
ABAntonia V Bennett
Antonia V Bennett
ADAmylou C. Dueck
Amylou C. Dueck
SMSandra A Mitchell
Sandra A Mitchell
TMTito R. Mendoza
Tito R. Mendoza
EBEthan Basch
Ethan Basch
PRO-CTCAE is a library of items that measure cancer treatment-related symptomatic adverse events (NCI Contracts: HHSN261201000043C and HHSN 261201000063C). The objective of this study is to examine the equivalence and acceptability of the three data collection modes (Web-enabled touchscreen tablet computer, Interactive voice response system [IVRS], and paper) available within the US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measurement system. Participants (n = 112; median age 56.5; 24 % high school or less) receiving treatment for cancer at seven US sites completed 28 PRO-CTCAE items (scoring range 0–4) by three modes (order randomized) at a single study visit. Subjects completed one page (approx. 15 items) of the EORTC QLQ-C30 between each mode as a distractor. Item scores by mode were compared using intraclass correlation coefficients (ICC); differences in scores within the 3-mode crossover design were evaluated with mixed-effects models. Difficulties with each mode experienced by participants were also assessed. 103 (92 %) completed questionnaires by all three modes. The median ICC comparing tablet vs IVRS was 0.78 (range 0.55–0.90); tablet vs paper: 0.81 (0.62–0.96); IVRS vs paper: 0.78 (0.60–0.91); 89 % of ICCs were ≥0.70. Item-level mean differences by mode were small (medians [ranges] for tablet vs. IVRS = −0.04 [−0.16–0.22]; tablet vs paper = −0.02 [−0.11–0.14]; IVRS vs paper = 0.02 [−0.07–0.19]), and 57/81 (70 %) items had bootstrapped 95 % CI around the effect sizes within +/−0.20. The median time to complete the questionnaire by tablet was 3.4 min; IVRS: 5.8; paper: 4.0. The proportion of participants by mode who reported “no problems” responding to the questionnaire was 86 % tablet, 72 % IVRS, and 98 % paper. Mode equivalence of items was moderate to high, and comparable to test-retest reliability (median ICC = 0.80). Each mode was acceptable to a majority of respondents. Although the study was powered to detect moderate or larger discrepancies between modes, the observed ICCs and very small mean differences between modes provide evidence to support study designs that are responsive to patient or investigator preference for mode of administration, and justify comparison of results and pooled analyses across studies that employ different PRO-CTCAE modes of administration. NCT Clinicaltrials.gov identifier: NCT02158637

20 March 2017 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
TMTito R Mendoza
Tito R Mendoza
ADAmylou C Dueck
Amylou C Dueck
ABAntonia V Bennett
Antonia V Bennett
SMSandra A Mitchell
Sandra A Mitchell
BRBryce B Reeve
Bryce B Reeve
EBEthan Basch
Ethan Basch
Aims: The US National Cancer Institute recently developed the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g. nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-, 2-, 3-, and 4-week recall periods, using daily reporting as the reference. Methods: English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four US cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-, 2-, 3-, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g. maximum of daily scores over 7 days vs 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores. Results: A total of 127 subjects completed questionnaires (57% male; median age: 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size) was −0.20 (−0.20) for 1-week recall, −0.36 (−0.31) for 2-week recall, −0.45 (−0.39) for 3-week recall, and −0.47 (−0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54–0.82), for 2-week recall was 0.74 (range: 0.58–0.83), for 3-week recall was 0.72 (range: 0.61–0.84), and for 4-week recall was 0.72 (range: 0.64–0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores. Conclusion: A 1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.